Physician profile
Keith Koepke
NPI 1851388391
$6,529.49
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,828 · 2020: $1,292 · 2021: $1,388 · 2022: $1,653 · 2023: $350 · 2024: $17.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $905.26 | 2019-2022 | |
| Novo Nordisk INC | $766.59 | 2019-2022 | |
| Lilly USA, LLC | $514.47 | 2019-2023 | Mounjaro |
| Amgen INC. | $477.09 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $441.65 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $422.95 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $401.09 | 2019-2022 | |
| Abbvie INC. | $368.59 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $307.05 | 2021 | |
| Abbott Laboratories | $252.08 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $229.15 | 2019-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $188.75 | 2020-2022 | |
| Astellas Pharma US INC | $185.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.56 | 2020-2024 | Ofev |
| Merck Sharp & Dohme LLC | $152.15 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $139.90 | 2020-2023 | |
| Kowa Pharmaceuticals America, INC. | $120.92 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.73 | 2022-2023 | |
| Esperion Therapeutics, INC. | $71.47 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $62.90 | 2019 | |
| Allergan, INC. | $56.33 | 2020 | |
| Melinta Therapeutics, LLC | $31.31 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.80 | 2019 | |
| Pfizer INC. | $16.10 | 2023 | |
| Collegium Pharmaceutical, INC. | $15.94 | 2021 | |
| Horizon Therapeutics Plc | $14.21 | 2023 | Krystexxa |
| Exact Sciences Corporation | $14.16 | 2023 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $13.83 | 2022 | |
| Nabriva Therapeutics, Plc | $12.88 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.72 | 2019 | |
| Neurocrine Biosciences, INC. | $12.55 | 2022 | |
| Daiichi Sankyo INC. | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Koepke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.